

## **GODAVARI DRUGS LIMITED**

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

14.11.2025

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting of Godavari Drugs Limited (the Company) held on Friday 14th November, 2025

Ref: Reg. 30 read with Reg. 33 of SEBI (LODR) Regulations, 2015

We wish to inform you that the Board of Directors of the Company at their meeting held on today, i.e. November 14, 2025 has, inter alia, transacted the following business:

 Considered and approved the un-audited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2025 with limited review report as recommended by the Audit Committee and reviewed by the Statutory Auditors.,

The Board Meeting Commenced at 03:30 P.M and concluded at 04:00 PM

A Copy of said results together with the limited review report is enclosed herewith for the Second quarter and half year ended September 30, 2025 are enclosed herewith.

These are also made available on the website of the company at www.godavaridrugs.com

This is for your information and records.

Thanking You, For Godavari Drugs Limited

Venkatesh Achanta Company Secretary & Compliance Officer Membership Number : A53326

Plant: A-6/2, MIDC, Nanded - 431 603. MS, India. E-mail: nnd@godavaridrugs.comCIN:L24230TG1987PLC008016

## GODAVARI DRUGS LIMITED

CIN: L24230TG1987PLC008016

Regd Office: "Mayfair", S.P.Road, Seunderabad, 500003

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR SIX MONTHS AND QUARTER ENDED SEPTEMBER 30, 2025

Rs.in Lakhs

SI.		Quarter ended			Half Year ended		Year ended	
N	Particulars	30.09.2025				30.09.2024	31.03.2025	
0.				The second secon	THE PERSON NAMED IN COLUMN 2 I	(Unaudited)	(Audited)	
1	Revenue from operations	2664.94	The second second	Andrew Property and Personal Property and Pr	5046.07	5829.54	11335.01	
2	Other Income	63.54	-		64.76	77.45	97.72	
3	Total Revenue from operations (1+2)	2728.48			5110.83		11432.73	
4	Expenses							
	(a) Cost of materials consumed	2399.24	1798.93	1697.53	4198.17	4392.36	8523.96	
	Changes in inventories of finished goods (b) & work-in-progress	-388.23			-473.64		-358.20	
	(c) Employee benefits expense	144.28			279.95		502.81	
	(c) Employee benefits expense	144.20	100.07	107.01	210.00	204.04	002.01	
	(d) Depreciation & amortization expense	60.37	60.43	58.22	120.80	113.18	244.76	
	(e) Finance Costs	90.84	The second secon		191.30		473.20	
	(f) Other Expenses	309.85			551.89		1483.66	
	(i) Charlesponde	000.00	212.01	120.00	001100	00 1100	1100.00	
	Total expenses	2616.35	2252.12	2484.52	4868.47	5580.57	10870.19	
5	Profit before exceptional Items and tax (3-							
	4)	112.13	130.23	125.21	242.36	326.42	562.54	
6	Exceptional items	150		- 31		-		
7	Profit before Tax (5-6)	112.13	130.23	125.21	242.36	326.42	562.54	
8	Tax expense	-12.06	-26.17	-16.35	-38.23	-54.48	-124.54	
9	Net Profit for the period (7-8)	100.07	104.06		204.13	271.94	438.00	
_	Other Comprehensive Income						-	
	Items that will not be reclassified to profit (i) or loss			*	*			
	(ii) Income tax relating to Items that will not be reclassified to profit or loss							
	Items that will be reclassified to profit or (iii) loss	-			-			
	(iv) Income tax relating to Items that will be reclassified to profit or loss		-		-	-		
	Total Other Comprehensive Income (Net of Tax)		-					
11	Total Comprehensive Income (9+10)	100.07	104.06	108.86	204.13	271.94	438.00	
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05	
13	Other Equity	(IEILE EN					3581.56	
14	Earnings per share (of Rs. 10/- each ) (not annualized)							
	(a) Basic	1.33	1.38	1.45	2.71	3.61	5.82	
	(b) Diluted	1.33						

- 1) The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on November 14,2025
- 2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- 3) The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5<sup>th</sup> July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
- 4) Corresponding figures in previsous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

Wholetime Director & CFO

DIN: 03405414

Place: Secunderabad Date: 14.11.2025

## GODAVARI DRUGS LIMITED Statement of Assets and Liabilities

Rs.in Lakhs

		Period ended	Year ended
I.Na	Particulars	30.09.2025	31.03.2025
.NO	1 al dedial 3	(Unaudited)	(Audited)
A	ASSETS		
_	Non-current assets		
		3141.40	3260.88
	(a) Property, Plant and Equipment	4088.23	2994.61
	(b) Capital work-in-progress		
	(c) Investment Property		
	(d) Goodwill		
	(e) Other Intangible assets		
	(f) Intangible assets under development		
	(g) Biological Assets other than bearer plant		
	(h) Financial Assets	0.01	0.01
	(i) Investments (ii) Trade Receivables	0.01	
	(iii) Loans (iv) Other (to be specified)	177.04	175.84
			*
	(i) Deferred tax assets (net)		
_	(j) Other non-current assets		
2	Current assets	000400	0704.10
	(a) Inventories	3624.29	2794.13
	(b) Financial Assets		
	(i) Investments		4000.00
	(ii) Trade Receivables	4178.81	4232.36
	(iii) Cash and cash equivalents	229.31	237.33
	(iv) Bank balances other than (iii) above		400.04
	(v) Loans	93.30	102.21
	(vi) Other (to be specified)		
	(c) Loans		510.00
	(d) Other current assets	713.98	510.27
Tota	al Assets	16246.37	14307.64
1 1	EQUITY AND LIABILITIES  EQUITY (a) Equity Share Capital	753.05	753.05
	(b) Other Equity	3785.68	3581.56
2	LIABILITIES		
	Non-current assets		
	(a) Financial Liabilities		
	(i) Borrowings	2986.15	2389.52
	(ii) Trade Payable		
	(iii) Other financial liabilities (other than those		
	specified in item (b), to be specified)		
	(b) Provisions	91.35	82.64
	(c) Defferred Tax liabilities (net)	188.64	191.84
	(d) Other non-current liabilities		
1	Il Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	4406.68	3773.25
	(ii) Trade Payable		
	A. Total outstanding dues of microenterprises small enterprises		
		28.24	31.5
	B. Total outstanding dues creditors other than of microenterprises and small enterprises	3057.07	2839.0
	(iii) Other financial liabilities (other than those spe in item (c)	789.06	546.1
	B. Other Current liabilities		
	(c) Provisions		
	(d) Current Tax Liabilities (net)	160.45	119.0
-	tal Equity and Liabilities	16246.37	14307.6
To			

For GODAVARI DRUGS LIMITED

Mohit Jaju

Wholetime Director & CFO

DIN: 03405414

Place: Secunderabad Date: 14.11.2025

## **GODAVARI DRUGS LIMITED** CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER, 2025

Rupees in lakhs

Particulars	Period ended \\ 30.09.2025 (Un Audited)	(eare ended 31.03.2025 (Audited)
A. Cash Flow from Operating Activities		
Profit before Depreciation, Interest and Tax	554.45	1,280.50
Less : Other Income considered separately	(64.76)	(97.72)
Net	489.69	1,182.78
(Increase) / Decrease in Inventories	(830.17)	(729.09)
(Increase) / Decrease in Receivables	53.55	1,709.97
(Increase) / Decrease in short term loans & advances	(194.80)	(34.06)
Increase / (Decrease) in Current Liabilities including current tax liab	1,091.03	(1,010.00)
Total A	609.30	1,119.60
B. Cash Flow from Investing Activities		
(Increase)/Decrease in Fixed assets	(1,094.93)	(1,999.81)
(Increase)/Decrease in Non current assets	(1.20)	(49.12)
Other Income	64.76	97.72
Total B	(1,031.37)	(1,951.21)
C. Cash Flow from Financing Activities		
Increase/(Decrease) in Long Term Borrowings	596.63	1,272.78
Increase/(Decrease) in Long Term Provisions	8.72	7.07
Interest Paid	(191.30)	(473.20)
Total C	414.05	806.65
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]	(8.02)	(24.96)
Cash and cash equivalents at the beginning of the year	237.33	262.29
Cash and cash equivalents at the end of the Period	229.31	237.33
Increase/(-)Decrease	(8.02)	(24.96

Place: Secunderabad Date: 14.11.2025

Wholetime Director & CFO

FOR GODAVARI DRUGS LIMITED

DIN: 03405414



1-2-386/A/1, Gagan Mahal Hyderabad - 500 029 Ph +91-40-27632354, 27642952 e-mail sridevar@yahoo co.in URL www.ayyadevara.com

Independent Auditor's Review Report on Standalone unaudited six months and quarter ended 30.09.2025 financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors Godavari Drugs Limited Secunderabad.

We have reviewed the accompanying statement of unaudited standalone financial results of Godavari Drugs Limited (the Company) for the six months and quarter ended 30<sup>th</sup> September 2025 (the statement), This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepare policies hance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co., Chartered Accountants

FRN: 00278S

Ayyadevara Srinivas

Proprietor

ICAI Membership No. 028803 Hyderabad. November 14, 2025

UDIN: 25028803BMUJUP6666

